Conditions: Prostatic Neoplasms
Allocation:  | Intervention model: PARALLEL
Enrollment: 87
Healthy volunteers: no

Brief summary:
The primary objective of this trial is to estimate and compare the 12-week progression-free rate of BIBF 1120, BIBW 2992 or sequential administration of BIBF 1120 and BIBW 2992 in patients with HRPC as determined by radiographic, bone and PSA criteria.

Detailed description:

Arms:

Interventions: intervention 1: BIBF 1120 intervention 2: BIBW 2992 intervention 3: Sequential BIBF 1120 + BIBW 2992
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: